Finally, we correlated intratumoral EpCAM heterogeneity groups with serum AFP-levels, another surrogate marker for poor prognosis [11], and major clinical endpoints such as TTR and RFS in order to understand whether EpCAM-expression pattern determines HCC subgroups with poor prognosis. The gene discussed is TTR; the disease is hepatocellular carcinoma.